{"id":"NCT01473836","sponsor":"Pfizer","briefTitle":"A Phase 3 Study Of Intravenous Metronidazole For Intrabdominal Infection","officialTitle":"A Phase 3, Multicenter, Unblind, Non-Comparative Study To Confirm Efficacy And Safety Of Intravenous Metronidazole In Patients With Intrabdominal Infection In Combination With Intravenous Ceftriaxone","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-11","primaryCompletion":"2012-10","completion":"2012-10","firstPosted":"2011-11-17","resultsPosted":"2013-12-10","lastUpdate":"2014-01-24"},"enrollment":38,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Intra-abdominal Infections"],"interventions":[{"type":"DRUG","name":"Metronidazole","otherNames":[]},{"type":"DRUG","name":"Ceftriaxone sodium","otherNames":["ROCEPHIN"]}],"arms":[{"label":"Metronidazole","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the clinical efficacy and safety in Japanese adult subjects with Intra-abdominal/Pelvic infections receiving Metronidazole IV 1,500-2,000 mg/day in combination with ceftriaxone sodium.","primaryOutcome":{"measure":"Clinical Response: Response Rate (Data Review Committee Assessment)","timeFrame":"Baseline to EOT (up to 14 days), TOC","effectByArm":[{"arm":"Metronidazole/Ceftriaxone","deltaMin":96.6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":15,"countries":["Japan"]},"refs":{"pmids":["25442806"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A6831005&StudyName=A%20Phase%203%20Study%20Of%20Intravenous%20Metronidazole%20For%20Intrabdominal%20Infection"]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":38},"commonTop":["Diarrhoea","Ileus paralytic","Insomnia","Nausea","Vomiting"]}}